SEMPRE Partners with Radisys to Develop Resilient and Secure 5G Infrastructure
Radisys® Corporation, a global leader of open telecom solutions, today announced a new partnership with SEMPRE, specializing in hardened digital infrastructure made in the USA. This partnership focuses on developing advanced and ruggedized technology to deliver secure and resilient O-RAN networks for military and civilian use. Radisys’ cutting-edge open RAN solution and proven expertise in network modernization are seamlessly integrated with SEMPRE’s state-of-the-art design to deliver a robust tactical network designed to connect authorized devices within highly secure environments, ensuring unparalleled reliability and protection. Together, they are delivering secure, resilient 5G networks designed to keep defense and commercial operations connected when it matters most.
SEMPRE revolutionizes connectivity with an easy-to-deploy and manage decentralized network. From hardware to software, the architecture is built on an uncompromising security-is-everything principle. Designed for global scalability, this solution leverages Radisys’ 3GPP and O-RAN compliant 5G RAN software, supporting multiple frequency bands to deliver secure, high-capacity, high-performance networks for defense and commercial customers.
SEMPRE provides integrated private 5G, edge computing, hybrid cloud access and satellite connectivity in a hardened enclosure that is designed to operate independently or with existing networks. SEMPRE’s patented satellite-based control plane and air-gapped management system ensure secure data transmission and real-time monitoring in any environment. This guarantees uninterrupted, secure communication for defense and commercial users—anytime, anywhere.
Radisys 5G CU/DU software won the final stage awards in the U.S. DoD/NTIA 5G Challenge 2022 and 2023 editions, including the award for best SBOM in 2022. Radisys has been a trusted RAN vendor for many ruggedized defense and public safety deployments with highly optimized footprint and ready portability on multiple platforms leveraging hardware and software security features to provide secure and robust 5G connectivity.
“Over the past year, SEMPRE has worked closely with Radisys to optimize its O-RAN stack for security and survivability, ensuring it can operate in both centralized and decentralized configurations,” said Rob Spalding, CEO of SEMPRE. “This collaboration expands the boundaries of survivable cellular networks, and we’re excited about the innovations ahead.”
“Securing communications infrastructure and ensuring its availability at all times is absolutely critical to defense and public safety networks, and we are delighted to partner with SEMPRE in delivering this promise,” said Arun Bhikshesvaran, CEO of Radisys. “Our partnership ensures continued service, even under adverse conditions, offering both immediate and long-term value in terms of security, uptime, and operational continuity, essential for defense and national security operations. We look forward to continuing this collaboration to deliver innovative and security-hardened solutions for defense and commercial networks.”
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital endpoints to disaggregated and open access and core solutions to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.
About SEMPRE
SEMPRE delivers mission-critical connectivity with private 5G, high-performance edge, hybrid cloud access and a SATCOM gateway—all in one easy-to-operate, hard-to-destroy system. Whether the mission requires a permanent network or transportable one that’s fully operational in 10 minutes, SEMPRE ensures resilient, secure communication when it matters most. SEMPRE ensures you can deploy anywhere and operate everywhere. For more information, visit www.sempre.ai.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226911067/en/
Contacts
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom